Leggatt Graham R, Frazer Ian H
Diamantina Institute for Cancer, Immunology and Metabolic Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia.
Curr Opin Immunol. 2007 Apr;19(2):232-8. doi: 10.1016/j.coi.2007.01.004. Epub 2007 Feb 12.
Vaccines prophylactic against infection with human papillomavirus (HPV) are based on alum adjuvanted virus-like particles. Two such vaccines have recently been shown to prevent persistent HPV infection and associated cervical cancer precursor lesions. The genotype-specific neutralising antibody directed at conformational epitopes of the L1 major capsid protein is likely to mediate protection. Vaccines therapeutic for persisting HPV infection can eliminate transplantable tumors in animal models, but are of limited efficacy in mice grafted with skin that expresses HPV antigens or in humans. This paradox has been partially resolved by data clarifying the immunoregulatory role of skin cytokines (e.g. transforming growth factor-beta and interleukin-10) and the consequences of antigen presentation by subsets of skin-associated antigen-presenting cells.
预防人乳头瘤病毒（HPV）感染的疫苗是基于明矾佐剂的病毒样颗粒。最近已证明两种此类疫苗可预防持续性HPV感染及相关的宫颈癌前病变。针对L1主要衣壳蛋白构象表位的基因型特异性中和抗体可能介导保护作用。用于治疗持续性HPV感染的疫苗可在动物模型中消除可移植肿瘤，但对移植了表达HPV抗原皮肤的小鼠或人类的疗效有限。通过阐明皮肤细胞因子（如转化生长因子-β和白细胞介素-10）的免疫调节作用以及皮肤相关抗原呈递细胞亚群进行抗原呈递的后果的数据，这一矛盾已得到部分解决。
